Tofacitinib: New drug in the therapeutic armamentarium in ocular inflammation
Authors:
Open Access
- 27 May 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 74 (6) , 845-850
Abstract
Tofacitinib, an oral Janus kinase (JAK) inhibitor, has established efficacy in the management of several autoimmune and inflammatory disorders, including rheumatoid arthritis, psoriatic arthritis, dermatitis, and ulcerative colitis. By inhibiting JAK phosphorylation, tofacitinib modulates cytokine-mediated inflammatory responses through interference with the JAK-STAT signaling pathway. In recent years, accumulating real-world evidence from India has suggested a beneficial role for tofacitinib in the management of ocular inflammatory diseases, particularly in patients with refractory disease who have failed conventional disease-modifying antirheumatic drugs and biologic therapies. Factors such as oral administration, rapid clinical response, ease of monitoring, and relative affordability compared with biologics have facilitated its wider adoption in routine clinical practice in the Indian setting. This review discusses the drug tofacitinib, mode of action, safety profile, its utility in non-infectious uveitis and with a particular emphasis on real-world data and socioeconomic considerations relevant to resource-limited settings.Keywords
This publication has 39 references indexed in Scilit:
- Real-World Clinical Equivalence of Generic and Branded Tofacitinib: A Prospective Longitudinal Cohort Study in Patients With Rheumatoid ArthritisMayo Clinic Proceedings, 2024
- Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western IndiaClinical Rheumatology, 2022
- Tofacitinib for refractory ocular mucous membrane pemphigoidAmerican Journal of Ophthalmology Case Reports, 2021
- JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitisClinical Rheumatology, 2020
- Tofacitinib for refractory uveitis and scleritisAmerican Journal of Ophthalmology Case Reports, 2019
- Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III StudyArthritis & Rheumatology, 2019
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitorSeminars in Arthritis and Rheumatism, 2016
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye DiseaseOphthalmology, 2012